DaVita Inc.

DaVita HealthCare (DVA) Falls More Steeply Than Broader Market: What Investors Need to Know

DaVita HealthCare (DVA) closed at $183.64 in the latest trading session, marking a -1.32% move from the prior day.

DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally?

DaVita's 55.6% stock rally reflects stronger operating execution, improving treatment volumes and value-based kidney care gains despite reimbursement pressures.

DaVita Inc. $DVA Position Lifted by CWA Asset Management Group LLC

CWA Asset Management Group LLC grew its stake in DaVita Inc. (NYSE: DVA) by 15.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 26,064 shares of the company's stock after purchasing an additional 3,574 shares during the period. CWA Asset

DaVita Inc. Schedules 3rd Quarter 2026 Investor Conference Call

DENVER, Oct. 19, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Thursday, October 29, 2026, at 5:00 p.m. Eastern Time.

18,685 DaVita Inc. $DVA Shares Acquired by Counterpoint Mutual Funds LLC

DaVita Brings New Clinical Research to ASN Kidney Week 2026, Advancing Evidence for the Next Era of Kidney Care

Seven studies spanning middle molecule clearance, home dialysis and patient experience highlight DaVita's commitment to translating innovation into better care DENVER, Oct. 15, 2026 /PRNewswire/ -- DaVita will present seven studies at the American Society of Nephrology (ASN) Kidney Week 2026, marking one of its most significant research presences at the conference in recent years. The research spans emerging approaches to middle molecule clearance, home dialysis and patient experience, underscoring DaVita's role in generating clinical evidence to help advance kidney care.

Why DaVita HealthCare (DVA) Outpaced the Stock Market Today

In the latest trading session, DaVita HealthCare (DVA) closed at $179.25, marking a +1.26% move from the previous day.

DaVita: After A 25% Drop, The Buyback Machine Is Cheap Again

DaVita is rated Buy with a $220 12-month price target, offering 22% upside from current levels. Despite flat industry volumes and Medicare rate headwinds, DVA's aggressive buybacks drive most EPS growth, enhancing per-share value. At $180, DVA trades at 9.4x forward earnings, making buybacks more accretive and capital allocation more effective than at recent highs.